 | ||
 |
 |
 |
 |
 |
 |
|
KANE BIOTECH INC. is a biotechnology company engaged in the development of products to prevent and disperse biofilms. Biofilms are a major cause of a number of serious medical problems including chronic infections and medical device related infections. They develop on surfaces such as catheters, prosthetic implants, teeth, lungs and the urogenital tract. Biofilms are pervasive, costly to deal with and approximately 80% of all human bacterial infections involve biofilms. The healing of chronic wounds alone costs the Unites States health care system $20 Billion per year.
LATEST NEWS
July 20, 2010
Kane Biotech Appoints Dr. Jeffrey B. Kaplan to Scientific Advisory Board
Kane Biotech Inc. (TSX-V:KNE), a biotechnology company engaged in the development of products that prevent and disperse microbial biofilms, is pleased to announce the appointment of Dr. Jeffrey B. Kaplan to its Scientific Advisory Board. Dr. Jeffrey B. Kaplan is an Associate Professor in the Department of Oral Biology at the University of Medicine and Dentistry of New Jersey and the discoverer of the antibiofilm enzyme DispersinB®. Read more
June 29, 2010
DispersinB® Technology for Development of Disease Resistant Biotech Crops
Kane Biotech Inc. (TSX-V:KNE), a biotechnology company engaged in the development of products that prevent and disperse microbial biofilms, is pleased to announce the invention of biotech plants producing DispersinB® antibiofilm enzyme. This provides a proof of concept for developing bacterial disease resistant agricultural crops of economic importance. Read more
February 23, 2010
Kane Biotech's Antibiofilm Technologies Published in Two New Scientific Books
Kane Biotech Inc. (TSX-V:KNE), a biotechnology company engaged in the development of products that prevent and disperse microbial biofilms is pleased to announce that the Company’s Research and Development (R&D) team has made contributions to two new scientific books. At the invitation of the publishers, Humana Press and Nova Science Publishers, respectively, Kane Biotech’s team has authored two book chapters reviewing their biofilm research methodology and the antibiofilm-antimicrobial technology development strategy for bacterial infection control. Read more
January 20, 2010
DispersinB® patent issues in AustraliaKane Biotech Inc. (TSX-V: KNE), a biotechnology company engaged in the development of products that prevent and disperse microbial biofilms, is pleased to announce the issuance of Patent No. 2003284385 entitled “Compositions and methods for enzymatic detachment of bacterial and fungal biofilms” by IP Australia (Australian Patent and Trademark Office). Australia is the third country to issue a patent covering Kane Biotech’s DispersinB® anti-biofilm technology. Read more
